BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Özkan A, Stolley D, Cressman ENK, McMillin M, DeMorrow S, Yankeelov TE, Rylander MN. The Influence of Chronic Liver Diseases on Hepatic Vasculature: A Liver-on-a-chip Review. Micromachines (Basel) 2020;11:E487. [PMID: 32397454 DOI: 10.3390/mi11050487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Du K, Li S, Li C, Li P, Miao C, Luo T, Qiu B, Ding W. Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply. Acta Biomater 2021:S1742-7061(21)00444-X. [PMID: 34265474 DOI: 10.1016/j.actbio.2021.07.013] [Reference Citation Analysis]
2 Özkan A, Stolley DL, Cressman ENK, McMillin M, DeMorrow S, Yankeelov TE, Rylander MN. Tumor Microenvironment Alters Chemoresistance of Hepatocellular Carcinoma Through CYP3A4 Metabolic Activity. Front Oncol 2021;11:662135. [PMID: 34262860 DOI: 10.3389/fonc.2021.662135] [Reference Citation Analysis]
3 Huang D, Zhang X, Fu X, Zu Y, Sun W, Zhao Y. Liver spheroids on chips as emerging platforms for drug screening. Engineered Regeneration 2021;2:246-56. [DOI: 10.1016/j.engreg.2021.10.003] [Reference Citation Analysis]
4 Lee SY, Kim D, Lee SH, Sung JH. Microtechnology-based in vitro models: Mimicking liver function and pathophysiology. APL Bioeng 2021;5:041505. [PMID: 34703969 DOI: 10.1063/5.0061896] [Reference Citation Analysis]
5 Long Y, Niu Y, Liang K, Du Y. Mechanical communication in fibrosis progression. Trends Cell Biol 2022;32:70-90. [PMID: 34810063 DOI: 10.1016/j.tcb.2021.10.002] [Reference Citation Analysis]
6 Kolaric TO, Nincevic V, Kuna L, Duspara K, Bojanic K, Vukadin S, Raguz-Lucic N, Wu GY, Smolic M. Drug-induced Fatty Liver Disease: Pathogenesis and Treatment. J Clin Transl Hepatol 2021;9:731-7. [PMID: 34722188 DOI: 10.14218/JCTH.2020.00091] [Reference Citation Analysis]
7 Stolley DL, Crouch AC, Özkan A, Seeley EH, Whitley EM, Rylander MN, Cressman ENK. Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies. Pharmaceutics 2020;12:E1243. [PMID: 33419304 DOI: 10.3390/pharmaceutics12121243] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]